Pitcairn’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-968
| Closed | -$544K | – | 447 |
|
|
2025
Q3 | $544K | Buy |
968
+491
| +103% | +$278K | 0.04% | 334 |
|
|
2025
Q2 | $250K | Sell |
477
-207
| -30% | -$116K | 0.02% | 614 |
|
|
2025
Q1 | $434K | Sell |
684
-206
| -23% | -$142K | 0.03% | 466 |
|
|
2024
Q4 | $634K | Sell |
890
-72
| -7% | -$60.4K | 0.04% | 359 |
|
|
2024
Q3 | $1.01M | Buy |
962
+44
| +5% | +$49K | 0.06% | 274 |
|
|
2024
Q2 | $965K | Buy |
918
+80
| +10% | +$77.6K | 0.06% | 277 |
|
|
2024
Q1 | $807K | Buy |
838
+51
| +6% | +$48.5K | 0.05% | 295 |
|
|
2023
Q4 | $691K | Sell |
787
-5
| -0.6% | -$4.12K | 0.05% | 307 |
|
|
2023
Q3 | $652K | Buy |
792
+64
| +9% | +$50.3K | 0.05% | 293 |
|
|
2023
Q2 | $523K | Sell |
728
-13
| -2% | -$10K | 0.04% | 347 |
|
|
2023
Q1 | $609K | Buy |
741
+22
| +3% | +$16.6K | 0.06% | 296 |
|
|
2022
Q4 | $519K | Buy |
719
+30
| +4% | +$22.1K | 0.05% | 311 |
|
|
2022
Q3 | $475K | Buy |
689
+31
| +5% | +$19.5K | 0.05% | 300 |
|
|
2022
Q2 | $389K | Buy |
658
+31
| +5% | +$20.1K | 0.04% | 364 |
|
|
2022
Q1 | $438K | Buy |
627
+15
| +2% | +$9.49K | 0.04% | 400 |
|
|
2021
Q4 | $386K | Sell |
612
-3
| -0.5% | -$1.84K | 0.02% | 441 |
|
|
2021
Q3 | $373K | Sell |
615
-10
| -2% | -$6.21K | 0.03% | 433 |
|
|
2021
Q2 | $349K | Buy |
625
+6
| +1% | +$3.04K | 0.02% | 456 |
|
|
2021
Q1 | $293K | Buy |
619
+14
| +2% | +$6.82K | 0.02% | 497 |
|
|
2020
Q4 | $292K | Sell |
605
-10
| -2% | -$5.4K | 0.02% | 451 |
|
|
2020
Q3 | $344K | Sell |
615
-57
| -8% | -$34.6K | 0.03% | 329 |
|
|
2020
Q2 | $419K | Buy |
672
+31
| +5% | +$17.6K | 0.04% | 260 |
|
|
2020
Q1 | $313K | Sell |
641
-65
| -9% | -$26.8K | 0.04% | 285 |
|
|
2019
Q4 | $265K | Buy |
+706
| New | +$238K | 0.02% | 437 |
|
|
2019
Q3 | – | Sell |
-873
| Closed | -$274K | – | 547 |
|
|
2019
Q2 | $274K | Sell |
873
-760
| -47% | -$253K | 0.03% | 422 |
|
|
2019
Q1 | $670K | Buy |
1,633
+120
| +8% | +$49.4K | 0.07% | 172 |
|
|
2018
Q4 | $565K | Buy |
1,513
+2
| +0.1% | +$732 | 0.06% | 182 |
|
|
2018
Q3 | $610K | Sell |
1,511
-74
| -5% | -$28.2K | 0.06% | 209 |
|
|
2018
Q2 | $546K | Sell |
1,585
-40
| -2% | -$12.5K | 0.06% | 235 |
|
|
2018
Q1 | $559K | Sell |
1,625
-119
| -7% | -$41.4K | 0.06% | 225 |
|
|
2017
Q4 | $655K | Sell |
1,744
-67
| -4% | -$27.1K | 0.07% | 219 |
|
|
2017
Q3 | $810K | Sell |
1,811
-155
| -8% | -$73.8K | 0.09% | 162 |
|
|
2017
Q2 | $966K | Sell |
1,966
-126
| -6% | -$55.1K | 0.12% | 122 |
|
|
2017
Q1 | $811K | Buy |
2,092
+112
| +6% | +$41.5K | 0.1% | 149 |
|
|
2016
Q4 | $727K | Sell |
1,980
-219
| -10% | -$83.3K | 0.09% | 168 |
|
|
2016
Q3 | $884K | Sell |
2,199
-60
| -3% | -$24.1K | 0.11% | 139 |
|
|
2016
Q2 | $789K | Sell |
2,259
-14
| -0.6% | -$5.39K | 0.1% | 148 |
|
|
2016
Q1 | $819K | Sell |
2,273
-160
| -7% | -$65.9K | 0.1% | 158 |
|
|
2015
Q4 | $1.32M | Sell |
2,433
-235
| -9% | -$127K | 0.15% | 103 |
|
|
2015
Q3 | $1.24M | Buy |
2,668
+185
| +7% | +$99.3K | 0.16% | 103 |
|
|
2015
Q2 | $1.27M | Sell |
2,483
-296
| -11% | -$144K | 0.15% | 123 |
|
|
2015
Q1 | $1.25M | Sell |
2,779
-468
| -14% | -$198K | 0.14% | 121 |
|
|
2014
Q4 | $1.33M | Buy |
3,247
+24
| +0.7% | +$9.44K | 0.14% | 122 |
|
|
2014
Q3 | $1.16M | Buy |
3,223
+86
| +3% | +$28.8K | 0.13% | 136 |
|
|
2014
Q2 | $886K | Buy |
3,137
+391
| +14% | +$116K | 0.1% | 167 |
|
|
2014
Q1 | $825K | Sell |
2,746
-192
| -7% | -$59.2K | 0.09% | 174 |
|
|
2013
Q4 | $808K | Sell |
2,938
-359
| -11% | -$103K | 0.09% | 178 |
|
|
2013
Q3 | $1.03M | Buy |
3,297
+135
| +4% | +$35.5K | 0.13% | 142 |
|
|
2013
Q2 | $711K | Buy |
+3,162
| New | +$736K | 0.1% | 190 |
|
Other funds holding REGN
N
Pitcairn's REGN Position: Q4 2025 in Review
Pitcairn sold out of Regeneron Pharmaceuticals (REGN) in Q4 2025, closing a stake of 968 shares — an estimated $544K sold.
Pitcairn first reported a position in REGN in Q2 2013 and held it in 49 quarters. The position peaked at $1.33M in Q4 2014. 1,385 funds tracked by Wall St. Rank hold REGN as of Q4 2025.
- Pitcairn reported no remaining Regeneron Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
- Pitcairn sold 968 Regeneron Pharmaceuticals shares in Q4 2025, an estimated $544K.
- Pitcairn first reported a position in Regeneron Pharmaceuticals in Q2 2013 and held it in 49 quarters.
- Pitcairn's Regeneron Pharmaceuticals position peaked at $1.33M in Q4 2014.
- 1,385 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2025.
Based on Pitcairn's 13F filing for Q4 2025.